TRIUMVIRA IMMUNOLOGICS
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.
TRIUMVIRA IMMUNOLOGICS
Social Links:
Industry:
Biotechnology Clinical Trials Health Care
Founded:
2015-01-01
Address:
Austin, Texas, United States
Country:
United States
Website Url:
http://www.triumvira.com
Total Employee:
51+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
100 M USD
Technology used in webpage:
SPF Person Schema Microsoft Exchange Online Google Office 365 Mail Google Cloud GoDaddy DNS Google Cloud Oregon
Similar Organizations
Century Therapeutics
Century Therapeutics is a developer of allogeneic living drugs created to offer treatment for cancer.
Eureka Therapeutics
Eureka Therapeutics is a biotechnology company focusing on immunotherapies for the treatment of cancer.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Vittoria Biotherapeutics
Vittoria Biotherapeutics is a gene-edited cell therapeutics company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Myeloma Investment Fund
Myeloma Investment Fund investment in Series A - Triumvira Immunologics
Multiple Myeloma Research Foundation
Multiple Myeloma Research Foundation investment in Series A - Triumvira Immunologics
Northpond Ventures
Northpond Ventures investment in Series A - Triumvira Immunologics
Leaps by Bayer
Leaps by Bayer investment in Series A - Triumvira Immunologics
B Capital
B Capital investment in Series A - Triumvira Immunologics
ATEM Capital Fund LP
ATEM Capital Fund LP investment in Series A - Triumvira Immunologics
Northpond Ventures
Northpond Ventures investment in Series A - Triumvira Immunologics
Bloom Burton & Co.
Bloom Burton & Co. investment in Series A - Triumvira Immunologics
Centre for Commercialization of Cancer Immunotherapy
Centre for Commercialization of Cancer Immunotherapy investment in Series A - Triumvira Immunologics
Leaps by Bayer
Leaps by Bayer investment in Series A - Triumvira Immunologics
Key Employee Changes
Official Site Inspections
http://www.triumvira.com Semrush global rank: 5 M Semrush visits lastest month: 1.66 K
- Host name: 47.107.198.104.bc.googleusercontent.com
- IP address: 104.198.107.47
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Triumvira Immunologics"
Company Overview - Triumvira Immunologics | Car-T, …
Triumvira is developing unique, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat a broad range of …See details»
About Us - Triumvira Immunologics | Car-T, TCR, TAC Therapies …
©2025 Triumvira Immunologics. About Us; Leadership; Pipeline; TAC101-CLDN18.2; Careers; Contact; Privacy Policy; Terms & ConditionsSee details»
Triumvira Immunologics - Crunchbase Company Profile …
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co …See details»
Leaps by Bayer
Vision. Triumvira’s mission is to focus on improving the lives of patients. Grounded by a deep understanding of immunology and expertise in drug …See details»
Triumvira Immunologics - The Org
At Triumvira Immunologics, Inc., our team is dedicated to a vision of finding a cure and providing new hope for patients with life-threatening disease. Co-founded in 2015 by licensing …See details»
Triumvira Immunologics - Funding, Financials, Valuation & Investors
Triumvira Immunologics is an immunotherapy company that develops novel T cell therapies for cancer. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. ... How …See details»
Triumvira Immunologics - Leadership Team - The Org
The Leadership Team at Triumvira Immunologics plays a critical role in steering the company towards its mission of developing innovative cancer therapies. This team, composed of …See details»
Triumvira Company Profile - Office Locations, Competitors ... - Craft
Triumvira Immunologics is an immunotherapy company. Its T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major …See details»
Triumvira Immunologics (USA) Funding: $100M
May 28, 2025 Triumvira Immunologics is an immunotherapy company with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer …See details»
Triumvira Announces First Patient with HER2 ... - Business Wire
Sep 21, 2021 Triumvira is headquartered in Austin, Texas with research facilities in Hamilton, Ontario. ... C3i Center Inc. is a unique Canadian organization that accelerates the …See details»
Triumvira Immunologics: Revenue, Worth, Valuation
About Triumvira Immunologics. Triumvira Immunologics is a Biotech related company founded in 2015 and based in Austin with 90 employees an estimated revenue of $14M, and. It has 10 …See details»
Contact - Triumvira Immunologics | Car-T, TCR, TAC Therapies and ...
Connect with Triumvira. How can we help? Headquarters. 9433 Bee Cave Rd Building I, Suite 240, Austin, TX 78733 512-790-0222. Research Facilities. 270 Longwood Rd S Hamilton, ON …See details»
Triumvira Immunologics, Inc. (Triumvira Immunologics, Inc.) - 药物 …
May 7, 2025 了解Triumvira Immunologics, Inc. (Triumvira Immunologics, Inc.)公司的药物管线，治疗领域，技术平台，以及它的3项临床试验, 86篇新闻和14篇文献，疾病领域:肿瘤，免疫 …See details»
Paul Lammers, M.D., M.Sc. Joins Triumvira as President and Chief ...
Jan 4, 2018 Triumvira Immunologics Canada Inc. and Triumvira Immunologics USA Inc. today announced the appointment of Paul Lammers, M.D., M.Sc., as President andSee details»
Triumvira is Creating a Different Picture for Cancer Patients
Sep 21, 2021 Triumvira President and CEO Dr. Paul Lammers/Courtesy Triumvira Immunologics. Triumvira Immunologics has an alternative to chimeric antigen receptor (CAR) …See details»
Triumvira Announces First Patient with HER2-overexpressing
Sep 21, 2021 Triumvira's TAC01-HER2, which harnesses natural T cell activation, was manufactured on Lonza's proprietary Cocoon ® Platform at C3i Center Inc in Montréal, …See details»
Careers - Triumvira Immunologics | Car-T, TCR, TAC Therapies and ...
Our Culture . We are dedicated to fostering a collegial, fast-paced, and low ego environment that leads to productive collaboration. Putting patients at the heart of our work, we consistently …See details»
Tricia Tolivar On Technology, Teamwork, And Leading CAVA’s IPO
18 hours ago Tricia Tolivar is the CFO of CAVA, a Mediterranean-inspired fast-casual restaurant chain and category-defining brand that operates in nearly 400 locations across 26 states and …See details»
Triumvira is Creating a Different Picture for Cancer Patients
Thus, Triumvira was born, completed a $55 million Series A financing round in August 2020 and went on to make the number 5 spot on BioSpace’s Top Life Sciences Startups to Watch in …See details»
Trauma bonds: The real story of Toronto’s lost COVID leaders
4 days ago John Tory, Joe Cressy, Eileen de Villa and Matthew Pegg gave they everything they had to keep Toronto safe during the pandemic. This is what lost, and the surprising thing each …See details»